In an international multicenter randomized phase 3 clinical trial led by Dana-Farber Cancer Institute, researchers tested the addition of the immune checkpoint inhibitor (ICI) nivolumab to treatment with tivozanib for patients with advanced clear cell renal cell carcinoma, a form of kidney cancer.
Akura Medical secures $35M to pursue FDA clearance for thrombectomy device
Dive Brief: Akura Medical has closed a $35 million series B financing that it plans to leverage to apply for FDA 510(k) clearance for its
October 4, 2023